<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369719</url>
  </required_header>
  <id_info>
    <org_study_id>Desferal versus Osveral</org_study_id>
    <nct_id>NCT01369719</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload</brief_title>
  <official_title>Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hormozgan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hormozgan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral
      iron chelators reduce iron overload in transfusion dependent patients. The aim of this study
      is to compare the efficacy and safety of osveral and desferal in transfusional iron overload
      patients with β-Thalassemia and intermediate Thalassemia in Bandarabbas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded randomized controlled trial on Efficacy and safety of Osveral and
      Desferal in thalassemic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ferritin level</measure>
    <time_frame>8 months</time_frame>
    <description>ferritin level in months 4 and 8 of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>8 month</time_frame>
    <description>hemoglobin level at months 4 and 8 off the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug side effects</measure>
    <time_frame>8 months</time_frame>
    <description>Leuckopenia, thrombocytopenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Thalassemia</condition>
  <condition>Iron Overload</condition>
  <condition>Transfusion Related Complications</condition>
  <arm_group>
    <arm_group_label>Osveral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg oral osveral daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desferal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg/kg desferal for 6 nights in a week subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>osveral</intervention_name>
    <description>receive 20 mg/kg daily orally</description>
    <arm_group_label>Osveral</arm_group_label>
    <other_name>deferasirox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desferal</intervention_name>
    <description>40-50mg/Kg for 6 nights in each week subcutaneously</description>
    <arm_group_label>desferal</arm_group_label>
    <other_name>Deferoxamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed intermedia or major thalassemia

          -  More then 2 years old

          -  Serum Ferritin level &gt; 1000

          -  Normal Creatinine and Complete Blood Count (CBC)

        Exclusion Criteria:

          -  HCV, HBV or HIV positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fariba Mansoori, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hormozgan University of Medical Sciences (HUMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hormozgan University of Medical Sciences (HUMS)</name>
      <address>
        <city>Bandar abbas</city>
        <state>Hormozgan</state>
        <zip>79145-3388</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fariba Mansoori</name_title>
    <organization>Hormozgan University of Medical Sciences (HUMS)</organization>
  </responsible_party>
  <keyword>Thalassemia</keyword>
  <keyword>Iron overload</keyword>
  <keyword>transfusion</keyword>
  <keyword>osveral</keyword>
  <keyword>desferal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

